Shandong Sinobioway Biomedicine Co., Ltd.

SZSE:002581 Stock Report

Market Cap: CN¥7.8b

Shandong Sinobioway Biomedicine Past Earnings Performance

Past criteria checks 0/6

Shandong Sinobioway Biomedicine's earnings have been declining at an average annual rate of -37.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 3.3% per year.

Key information

-37.5%

Earnings growth rate

-37.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-3.3%
Return on equity-15.3%
Net Margin-85.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Oct 08
There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Aug 19
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Mar 06
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Revenue & Expenses Breakdown

How Shandong Sinobioway Biomedicine makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002581 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24406-34837339
30 Jun 24431-30840743
31 Mar 24438-33942958
31 Dec 23430-33242660
30 Sep 23420-4941546
30 Jun 23379-9241744
31 Mar 23345-3841130
01 Jan 23357-1542227
30 Sep 22362-1243937
30 Jun 2236615742633
31 Mar 2240824847435
01 Jan 2240327147638
30 Sep 2140225848533
30 Jun 213653446543
31 Mar 21258-10941645
31 Dec 20277-19642649
30 Sep 20324-9247351
30 Jun 20404-5551047
31 Mar 205431354057
31 Dec 195686354355
30 Sep 19606-6757663
30 Jun 19670-8458563
31 Mar 19644-19153149
31 Dec 18665-10454246
30 Sep 1889412947335
30 Jun 1892621743353
31 Mar 181,03939445846
31 Dec 171,16238847139
30 Sep 171,15142049828
30 Jun 171,2384425380
31 Mar 171,2784175350
31 Dec 161,2654185330
30 Sep 161,2303745240
30 Jun 161,0953164870
31 Mar 169562874480
31 Dec 158582504350
30 Sep 157072053920
31 Dec 146242253500
31 Dec 134011092660

Quality Earnings: 002581 is currently unprofitable.

Growing Profit Margin: 002581 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002581 is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.

Accelerating Growth: Unable to compare 002581's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002581 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 002581 has a negative Return on Equity (-15.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies